Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reissued by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports.

Several other analysts have also recently weighed in on SRPT. Royal Bank Of Canada decreased their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a research note on Wednesday, May 7th. Cantor Fitzgerald reissued a “neutral” rating on shares of Sarepta Therapeutics in a report on Monday, June 16th. Oppenheimer decreased their price target on Sarepta Therapeutics from $123.00 to $45.00 and set an “outperform” rating on the stock in a research report on Friday, June 20th. Piper Sandler downgraded Sarepta Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $70.00 to $36.00 in a research report on Monday, June 16th. Finally, The Goldman Sachs Group cut Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating and set a $29.00 target price on the stock. in a report on Tuesday, June 17th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Hold” and an average target price of $60.88.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock traded down $0.23 during midday trading on Wednesday, hitting $17.23. 6,649,704 shares of the company were exchanged, compared to its average volume of 2,125,194. The firm has a 50 day simple moving average of $40.94 and a 200-day simple moving average of $80.65. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The firm has a market cap of $1.69 billion, a P/E ratio of -6.41 and a beta of 0.61. Sarepta Therapeutics has a 52 week low of $16.99 and a 52 week high of $162.95.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm’s revenue for the quarter was up 80.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.73 EPS. Research analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. EP Wealth Advisors LLC raised its position in shares of Sarepta Therapeutics by 2.2% during the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock valued at $606,000 after acquiring an additional 105 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Sarepta Therapeutics by 5.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 145 shares during the period. Virtus ETF Advisers LLC increased its holdings in Sarepta Therapeutics by 6.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 174 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 194 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Sarepta Therapeutics by 95.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 216 shares during the period. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.